ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The feasibility of such an active immunotherapeutic approach with the absence of off-target events, high OS and a not-negligible rate of successful TFR could prompt newer vaccine strategies, such as mRNA BCR::ABL1 breakpoint vaccines for low-disease-burden CML patients in order to improve the current therapeutic path towards a cure.